| Literature DB >> 26371044 |
Veronika Pipan1, Minja Zorc2, Tanja Kunej3.
Abstract
Single nucleotide polymorphisms (SNPs) located in microRNA (miRNA) genes (miR-SNPs) have attracted increasing attention in recent years due to their involvement in the development of various types of cancer. Therefore, a systematic review on this topic was needed. From 55 scientific publications we collected 20 SNPs, which are located within 18 miRNA encoding genes and have been associated with 16 types of cancer. Among 20 miRNA gene polymorphisms 13 are located within the premature miRNA region, five within mature, and two within mature seed miRNA region. We graphically visualized a network of miRNA-cancer associations which revealed miRNA genes and cancer types with the highest number of connections. Our study showed that, despite a large number of variations currently known to be located within miRNA genes in humans, most of them have not yet been tested for association with cancer. MicroRNA SNPs collected in this study represent only 0.43% of known miRNA gene variations (20/4687). Results of the present study will be useful to researchers investigating the clinical use of miRNAs, such as the roles of miRNAs as diagnostic markers and therapeutic targets.Entities:
Keywords: cancer; microRNA (miRNA); single nucleotide polymorphisms (SNP)
Year: 2015 PMID: 26371044 PMCID: PMC4586796 DOI: 10.3390/cancers7030863
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Workflow of the study and main results.
Locations of SNPs within miRNA encoding genes and host genes.
| miRNA Name | rs Number | Substitution | Location | Genomic Context (Host Genes) | |
|---|---|---|---|---|---|
| Protein-Coding | Non-Coding Transcriptional Unit | ||||
| hsa-mir-27a | rs11671784 | G>A | pre-mature | ||
| rs895819 | T>A, T>C, T>G | pre-mature | |||
| hsa-mir-146a | rs2910164 | C>G | seed | CTC-231O11.1 (exon, S) | |
| hsa-mir-149 | rs71428439 | A>G | pre-mature | ||
| rs2292832 | T>C | pre-mature | |||
| hsa-mir-196a-2 | rs11614913 | C>T | mature | ||
| hsa-mir-202 | rs12355840 | C>A, C>T, C>G | pre-mature | ||
| hsa-mir-423 | rs6505162 | A>C | pre-mature | ||
| hsa-mir-499a | rs3746444 | A>G | seed | ||
| hsa-mir-603 | rs11014002 | C>T | pre-mature | ||
| hsa-mir-605 | rs2043556 | T>C | pre-mature | ||
| hsa-mir-608 | rs4919510 | C>G | mature | ||
| hsa-mir-612 | rs12803915 | G>A | pre-mature | ||
| hsa-mir-618 | rs2682818 | A>C | pre-mature | ||
| hsa-mir-646 | rs6513497 | T>G | mature | ||
| hsa-mir-933 | rs79402775 | G>A | mature | ||
| hsa-mir-1206 | rs2114358 | G>A | pre-mature | ||
| hsa-mir-1307 | rs7911488 | A>G | pre-mature | ||
| hsa-mir-3144 | rs67106263 | G>A | mature | ||
| hsa-mir-5197 | rs2042253 | T>C | pre-mature | ||
Host gene names: GPC1: Glypican 1, HOXC6: Homeobox C6, MIR202HG: MIR202 host gene, NSRP1: Nuclear speckle splicing regulatory protein 1, MIR3184: microRNA 3184 (hsa-mir-3184), MYH7B: Myosin, heavy chain 7B, cardiac muscle, beta, KIAA1217, PRKG1: Protein kinase, cGMP-dependent, type I, SEMA4G: Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G, MRPL43: Mitochondrial ribosomal protein L43, NEAT1: Nuclear paraspeckle assembly transcript 1 (non-protein coding), LIN7A: Lin-7 homolog A (C. elegans), MIR646HG: MIR646 host gene, ATF2: Activating transcription factor 2, PVT1: Pvt1 oncogene (non-protein coding), USMG5: Up-regulated during skeletal muscle growth 5 homolog (mouse). Host gene orientation abbreviation: S: sense, As: antisense.
Figure 2Network representing 75 associatons between 18 miRNA encoding genes and 16 types of cancer. MicroRNA encoding genes are presented as pink nodes while different types of cancer are shown as blue nodes. The size of a node correlates with the number of its associations. Red solid edges represent associations with negative outcome (increased risk of cancer, overall survival risk, unfavorable overall and recurrence-free survival, and increased risk of recurrence and death) and green dashed edges represent associations with positive outcome (decreased risk of cancer, better response to chemotherapy, increased survival, protective against mortality, favorable overall and recurrence-free survival, and decreased risk of recurrence). MicroRNA host genes are presented in parentheses.